C
Caladrix develops orally available small molecules that modulate ATP-binding cassette (ABC) transporters to restore the brain's innate clearance systems for treating Alzheimer's disease. This non-immunologic approach aims to reduce neurotoxic protein accumulation and neuroinflammation without the risk of ARIA associated with antibody therapies. The lead candidate, C-001, is advancing through clinical trials for early-stage Alzheimer's and has pipeline candidates for other tauopathies.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Caladrix develops orally available small molecules that modulate ATP-binding cassette (ABC) transporters to restore the brain's innate clearance systems for treating Alzheimer's disease. This non-immunologic approach aims to reduce neurotoxic protein accumulation and neuroinflammation without the risk of ARIA associated with antibody therapies. The lead candidate, C-001, is advancing through clinical trials for early-stage Alzheimer's and has pipeline candidates for other tauopathies.